Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis

The FDA has approved garadacimab-gxii (Andembry – CSL Behring), a subcutaneously injected inhibitor of activated clotting factor XII, for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. Garadacimab is the first activated factor XII inhibitor to become available in the US for HAE prophylaxis.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-11-10
DOI: https://doi.org/10.58347/tml.2025.1741c
Primary Topic: Coagulation, Bradykinin, Polyphosphates, and Angioedema
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis

Nov 10, 2025

The medical letter on drugs and therapeutics/The medical letter

Coagulation, Bradykinin, Polyphosphates, and Angioedema

article

Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis

November 10, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1741)

Openalex Percentile: Top 54%

Coagulation, Bradykinin, Polyphosphates, and Angioedema

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS